Human papillomavirus infection and vaccination among young females in rural Uganda
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70227 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Rob Newton und 6 weiteren Autor:innen. Beteiligte Einrichtung: MRC/UVRI Uganda Research Unit, Entebbe, Uganda. Hauptthemen laut MEDLINE: Papillomavirus Infections, Papillomavirus Vaccines, Vaccination, Uterine Cervical Neoplasms. Die Arbeit nennt 43 Literaturangaben. Gefördert von: World Health Organization, Gates Foundation, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Cervical cancer is the most common cancer in Uganda. In 2015, a national human papillomavirus (HPV) vaccination program was initiated, targeting girls aged 10 years. To provide a pre‐vaccination baseline to monitor HPV vaccine effectiveness, first‐void urine (FVU) samples were collected from females aged 16–21 years in the General Population Cohort (GPC) in South‐East Uganda, between 2019 and 2023. HPV vaccination status was obtained from questionnaires and vaccination cards. FVU samples were tested for 28 HPV types using Allplex HPV28. Among 1009 participants, 28 type prevalence was 33%, and was higher among females reporting sexual intercourse (aPR = 3.7, 95%CI 2.8–4.8) and HIV infection (PR = 1.4, 95%CI 1.1–1.8). HPV16/18 prevalence was 4.8% overall, and lower in 146 vaccinated (1.4%) than 783 unvaccinated (5.6%) females (aPR = 0.4, 95%CI 0.1–1.4). No decrease was observed in other high‐risk (aPR = 1.5, 95%CIs 1.0–2.2) or low‐risk (aPR = 1.4, 95%CIs 1.0–2.1) types which were more prevalent in vaccinated females. Among vaccinated 16–21 year‐olds, 30.8% ( n = 45) received one, 44.5% ( n = 65) two, and 14.3% ( n = 21) three doses. Vaccination status was also obtained from 1121 younger girls aged 10–15 years from the same GPC population, among whom 42.8% ( n = 480) were vaccinated, 47.1% ( n = 226) with one, 44.2% ( n = 212) two, and 6.7% ( n = 32) three doses. In conclusion, we report high HPV prevalence in young women in Uganda and see first impacts of vaccination on HPV16/18 infection. This population, shown to have suboptimal HPV vaccine coverage and heterogeneity in doses received, can serve as a robust baseline for future evaluations of HPV vaccine effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MRC/UVRI Uganda Research Unit, Entebbe, Uganda.
- University of York, York, UK.
- International Agency for Research on Cancer (IARC/WHO), Early Detection, Prevention and Infections Branch, Lyon, France.
- Centre for the Evaluation of Vaccination (CEV), Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Flanders, Belgium.
ORCID-Profile: Gary M Clifford
Förderung
- World Health Organization
- Gates Foundation
- Bill and Melinda Gates Foundation
Zitieren
APA
Newton, R., Tenet, V., Mugisha, J., Kimono, B., Vorsters, A., Bell, M., & Clifford, G. M. (2026). Human papillomavirus infection and vaccination among young females in rural Uganda. International Journal of Cancer. https://doi.org/10.1002/ijc.70227
Vancouver
Newton R, Tenet V, Mugisha J, Kimono B, Vorsters A, Bell M, et al. Human papillomavirus infection and vaccination among young females in rural Uganda. International Journal of Cancer. 2026. doi:10.1002/ijc.70227
BibTeX
@article{Newton2026,
author = {Newton, Rob and Tenet, Vanessa and Mugisha, Joseph and Kimono, Beatrice and Vorsters, Alex and Bell, Margo and Clifford, Gary M},
title = {Human papillomavirus infection and vaccination among young females in rural Uganda},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70227}
}
EUVIMED